within Pharmacolibrary.Drugs.ATC.R;

model R01AD09
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.001,
    Cl             = 1200 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 0.2 / 1000000,
    adminCount     = 1,
    Vd             = 0.012,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Mometasone is a synthetic corticosteroid with potent anti-inflammatory activity. It is mainly used as a nasal spray for the treatment of allergic rhinitis, and also in inhaled and topical forms to treat asthma and inflammatory skin conditions. Mometasone (as mometasone furoate) is approved and widely used today for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameter estimates for adults following intranasal administration of mometasone furoate nasal spray, based on available pharmacokinetic studies in healthy volunteers.</p><h4>References</h4><ol><li><p>Szefler, SJ (2001). Pharmacokinetics of intranasal corticosteroids. <i>The Journal of allergy and clinical immunology</i> 108(1 Suppl) S26–S31. DOI:<a href=&quot;https://doi.org/10.1067/mai.2001.115563&quot;>10.1067/mai.2001.115563</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11449203/&quot;>https://pubmed.ncbi.nlm.nih.gov/11449203</a></p></li><li><p>Patel, P, et al., &amp; Tantry, SK (2018). Pharmacokinetics of intranasal mometasone in the fixed-dose combination GSP301 versus two monotherapy intranasal mometasone formulations. <i>Allergy and asthma proceedings</i> 39(3) 232–239. DOI:<a href=&quot;https://doi.org/10.2500/aap.2018.39.4134&quot;>10.2500/aap.2018.39.4134</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29669668/&quot;>https://pubmed.ncbi.nlm.nih.gov/29669668</a></p></li><li><p>Onrust, SV, &amp; Lamb, HM (1998). Mometasone furoate. A review of its intranasal use in allergic rhinitis. <i>Drugs</i> 56(4) 725–745. DOI:<a href=&quot;https://doi.org/10.2165/00003495-199856040-00018&quot;>10.2165/00003495-199856040-00018</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9806113/&quot;>https://pubmed.ncbi.nlm.nih.gov/9806113</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R01AD09;
